Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial

Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2025 Poal.co

468

• (edited )

Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial (www.medrxiv.org)

Just posting this FWIW.

But Hoo-boy, it's full of kikes...

Asaf Biber, Michal Mandelboim, Geva Harmelin, Dana Lev, Li Ram, Amit Shaham, Ital Nemet, Limor Kliker, Oran Erster, Eli Schwartz

Just posting this FWIW. But Hoo-boy, it's full of kikes... >Asaf Biber, Michal Mandelboim, Geva Harmelin, Dana Lev, Li Ram, Amit Shaham, Ital Nemet, Limor Kliker, Oran Erster, Eli Schwartz

(post is archived)

[–] • 1 pt

Study sizes were far too small.

You need around 300, at the minimum, who complete the study arm and placebo arm. Preferred is 1,000.

This is had 34 complete the study arm (barely enough for a normalized sample set but in pharmaceuticals, 1,000 is the preferred study arm).

We have quite a few studies on Ivermectin - most show no benefit.

However, this preprint study is promising. Why? It's a true RCT. That's the type of quality study needed.

link